Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze? technology (rHuPH20, recombinant human hyaluronidase)...
More...